It is not certain that the new Wearable Behaviour Model (WBM) AI will make it into a finished product – not least because of ...

The acquisition – which will see MSD pay $107 for each American Depository Share (ADS) in UK-headquartered Verona – is the ...

Returning for its second year, the Autoimmunity & Inflammation Partnering & Investment Summit unites over 80 on-scope and ...

It is the second licensing deal that AbbVie has negotiated this year for a trispecific for multiple myeloma, coming in the ...

From robot-assisted surgery to personalised disease treatment - technology can do some truly remarkable things. But while the ...

The FDA has called a plan to publish certain complete response letters (CRLs) for medicines it has rejected after an initial ...

Technology has also improved immunisation operations with the use of online appointment scheduling that automates ...

So, what were the major themes to come out of BIO Boston 2025? Who’s getting excited about what? And – besides the obvious ...

Toymaker Mattel has launched its latest addition to the Barbie range of dolls, the first with type 1 diabetes, which comes ...

Apogee is pitching APG777 as a 'best-in-class' IL-13 inhibitor that could offer robust efficacy and less-frequent dosing than ...

New Evidation CEO Leslie Olay Wilberforce speaks at a Reuters event earlier this year. Earlier this year, San Francisco-based ...

On the forefront of healthcare change, turning innovative science into value for patients: Astellas at ASCO 2025 At this year ...